POLB — Poolbeg Pharma Income Statement
0.000.00%
Last trade - 00:00
- £49.00m
- £34.88m
- 18
- 10
- 89
- 29
2021 December 31st | 2022 December 31st | |
---|---|---|
Period Length: | 12 M | 12 M |
Source: | ARS | ARS |
Standards: | IFRS | IFRS |
Status: | Final | Final |
Revenue | ||
Total Revenue | 0 | 0 |
Cost of Revenue | ||
Gross Profit | 0 | 0 |
Selling / General / Administrative Expenses | ||
Research And Development | ||
Other Operating Expenses | ||
Total Operating Expenses | 2.34 | 4.99 |
Operating Profit | -2.34 | -4.99 |
Total Net Non Operating Interest Income / Expense | ||
Net Income Before Taxes | -2.34 | -4.78 |
Provision for Income Taxes | ||
Net Income After Taxes | -2.34 | -4.69 |
Net Income Before Extraordinary Items | ||
Net Income | -2.34 | -4.69 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||
Income Available to Common Shareholders Including Extraordinary Items | ||
Diluted Net Income | -2.34 | -4.69 |
Diluted Weighted Average Shares | ||
Basic EPS Including Extraordinary Items | ||
Diluted EPS Including Extraordinary Items | ||
Diluted EPS Excluding Extraordinary Items | ||
Normalised Income Before Taxes | ||
Normalised Income After Taxes | ||
Normalised Income Available to Common Shareholders | ||
Diluted Normalised EPS | -0.005 | -0.009 |
Dividends per Share |